Dayton Clinical Oncology Program accesses clinical trials through its membership in cooperative research groups funded by the National Cancer Institute (NCI), and through the pharmaceutical industry. For a listing of research groups and links to their web sites, go to the "Links to Other Sites" tab at the left.

CURRENTLY OPEN CLINICAL TRIALS:

GENERAL CANCER CONTROL TRIALS for SYMPTOM MANAGEMENT:

20050175 Effectiveness of a Comprehensive Intervention Program to Align Quality Standards for the Prevention of Clinically Significant Chemotherapy Induced Neutropenia Events in the Community Oncology Practice Seting. download schema and patient eligibility summary

AVF3991n Avastin in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent or Metastatic Breast Cancer. download schema and patient eligibility summary

MC04CC The Effects of Parenteral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin alfa for Cancer Patients with Chemotherapy-Associated Anemia. download schema and patient eligibility summary

N05C5 Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Xeloda-Induced Hand and Foot Syndrome. download schema and patient eligibility summary for patients registered prior to addendum 5    download schema and patient eligibility summary for patients registered after addendum 5

N05C7 Long Acting Concerta for Cancer-Related Fatigue. download schema and patient eligibility summary

URCC-04-02 (U1105) Prevention of Delayed Nausea. download schema and patient eligibility summary

CLINICAL TRIALS BY DISEASE SITE:

BREAST:

    BREAST CANCER CONTROL:

CALGB-70301 Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer. download schema and patient eligibility summary

N063I Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy. download schema and patient eligibility summary

    METASTATIC:

E1105 First Line Chemotherapy and Herceptin with or without Avastin for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer. download schema and patient eligibility summary

N0539 Faslodex and Avastin in Patients with Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor. download schema and patient eligibility summary

S0622 Two Different Schedules of Sprycel in Bone-Metastasis Predominant Metastatic Breast Cancer. download schema and patient eligibility summary

    NODAL:

CALGB-40101 Cytoxan & Adriamycin vs Taxol as Adjuvant Therapy for Women with Node-Negative Breast Cancer. download schema and patient eligibility summary

E5103 Adriamycin and Cytoxan followed by Taxol with Avastin or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer. download schema and patient eligibility summary

NSABP B-36 Adjuvant Therapy Comparing Six Cycles of 5-FU, Epirubicin and Cytoxan to 4 Cycles of Adriamycin and Cytoxan With or Without Celebrex, in Patients with Node-Negative Breast Cancer. download schema and patient eligibility summary

    BREAST OTHER:

ACOSOG-Z1041 Comparing a Neoadjuvant Regimen of FEC-75 Followed By Taxol Plus Herceptin with a Neoadjuvant Regimen of Taxol Plus Herceptin Followed By FEC-75 Plus Herceptin in Patients with Palpable and Operable Breast Cancer. download schema and patient eligibility summary

B-41-I Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Herceptin Plus Lapatinib to Herceptin and to Lapatinib Administered with Weekly Taxol Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response. download schema and patient eligibility summary

CALGB-40302 Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: Faslodex With or Without Lapatinib for Postmenopausal Women with Hormone Receptor Positive Advanced Breast Cancer. download schema and patient eligibility summary

FB-5 Epirubicin Plus Cytoxan Followed by Taxotere Plus Herceptin and Avastin Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer. download schema and patient eligibility summary

IBCSG-24-02 The Role of Ovarian Function Suppression and Aromasin as Adjuvant Therapies for Postmenopausal Women with Endocrine Responsive Breast Cancer. download schema and patient eligibility summary

N063D Adjuvant Lapatinib, Herceptin, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer. download schema and patient eligibility summary

NCIC-MA.27 Aromasin vs Arimidex with or without Celebrex in Postmenopausal Women with Receptor Positive Primary Breast Cancer. download schema and patient eligibility summary

NSABP-B-39 Conventional Whole Breast Irradiation vs Partial Breast Irradiation for Women with Stage 0, I, or II Breast Cancer. download schema and patient eligibility summary

NSABP-B-40 Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Xeloda or Gemzar to Taxotere when Administered Before AC with or without Avastin and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens. download schema and patient eligibility summary

NSABP-B-42 Five Years of Femara vs Placebo in Patients Completing 5 Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Postmenopausal Women with Hormone Receptor Positive Breast Cancer. download schema and patient eligibility summary

PACCT-1 Program for the Assessment of Clinical Cancer Tests: Trial Assigning Individualized Options for Treatment: The TAILORx Trial. download schema and patient eligibility summary

RC0639 Cardiac Safety and Tolerability of an Adjuvant Chemotherapy plus Herceptin with Lapatinib in Patients with Resected HER2+ Breast Cancer. download schema and patient eligibility summary

S0307 Bisphosphonates as Adjuvant Therappy for Primary Breast Cancer. download schema and patient eligibility summary

    BREAST COMPANION:

N0434 The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC-MA.27B The Influence of Five Years of Adjuvant Arimidex or Aromasin on Bone Mineral Density in Postmenopausal Women with Primary Breast Cancer. download schema and patient eligibility summary

NSABP-B-42Registration A Companion Clinical Trial for Completion of Hormonal Therapy Prior to Considering Enrolling in NSABP-B-42 Treatment Trial for Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.

GASTROINTESTINAL:

    GASTROINTESTINAL CANCER CONTROL:

CSTI571BUS227 Gastrointestinal Stromal Tumors Registry Protocol.

LTS-01 Patient Reported Outcomes in Long Term Survivors with Colon and Rectal Cancer. download schema and patient eligibility summary

    COLORECTAL:

ACOSOG-Z6041 Neoadjuvant Chemoradiation and Local Excision for uT2uNO Rectal Cancer. download schema and patient eligibility summary

E5202 5-FU, Leucovorin and Oxaliplatin vs 5-FU, Leukovorin, Oxaliplatin and Avastin in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers. download schema and patient eligibility summary

E5204 Postoperative Oxaliplatin, 5-FU, Leucovorin vs Oxaliplatin, 5-FU, Leucovorin and Avastin for Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation. download schema and patient eligibility summary

N0543 Pharmacogenetic-Based Dosing of Camptosar, Oxaliplatin, and Xeloda as First-Line Therapy for Advanced Small Bowel Adenocarcinoma. download schema and patient eligibility summary

NSABP-C-10 5-FU, Leucovorin, and Oxaliplatin Chemotherapy Plus Avastin for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor. download schema and patient eligibility summary

NSABP-R-04 Preoperative Radiation Therapy(RT) and Xeloda vs Preoperative RT and Continuous Intravenous Infusion of 5-FU in the Treatment of Patients with Operable Carcinoma of the Rectum. download schema and patient eligibility summary

    ESOPHAGEAL:

CALGB-80101 Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcenoma. download schema and patient eligibility summary

S0356 Oxaliplatin + Protracted Infusion 5-FU + Radiation for Potentially Curable Esophageal Cancer. download schema and patient eligibility summary

GENITOURINARY:

    BLADDER:

S0353 Intravesical Gemzar in Patients with Superficial Bladder Cancer Who Have Progressed Despite Intravesical BCG. download schema and patient eligibility summary

    PROSTATE TREATMENT:

CALGB-90203 Neo-Adjuvant Taxotere and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer. download schema and patient eligibility summary

E3805 CHAARTED: ChemoHormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer. download schema and patient eligibility summary

RTOG-0521 Androgen Suppression (AS) and 3D CRT/IMRT vs AS and 3D CRT/IMRT followed by Chemotherapy with Taxotere and Prednisone for Localized, High-Risk Prostate Cancer. download schema and patient eligibility summary

RTOG-0526 Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy. download schema and patient eligibility summary

RTOG-0534 Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy in Prostate Cancer Patients with Rising PSA After Radical Prostatectomy . download schema and patient eligibility summary

S0421 Taxotere +/- Xinlay for Patients with Advanced Hormone Refractory Prostate Cancer. download schema and patient eligibility summary

    RENAL:

E2805 Randomized, Double-Blind Phase III Trial of Adjuvant Sutent (Sunitinib) vs Nexavar (Sorafenib) vs Placebo in Patients with Resected Renal Cell Carconoma. download schema and patient eligibility summary

GYNECOLOGIC:

    CERVICAL/ENDOMETRIAL:

GOG-0209 Adriamycin (Doxorubicin)/Cisplatin/Taxol (Paclitaxel) and G-CSF vs Carboplatin/Taxol in Patients with Stage III & IV or Recurrent Endometrial Cancer. download schema and patient eligibility summary

GOG-0219 Weekly Cisplatin and Radiation vs Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB, and IVA Cervical Carcinoma Limited to the Pelvis. download schema and patient eligibility summary

RTOG-0417 Avastin in Combination with Definitive Radiotherapy and Cisplatin Chemotherapy in Untreated Patients with Locally Advanced Cervical Carcinoma. download schema and patient eligibility summary

RTOG-0418 Intensity Modulated Ratiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-operative Patients with either Endometrial or Cervical Carcinoma. download schema and patient eligibility summary

    OVARIAN/PERITONEAL:

GOG-0218 Carboplatin and Taxol (CT) Plus Placebo vs CT Plus Concurrent Avastin followed by Placebo, vs CT Plus Concurrent and Extended Avastin, in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Peritoneal Primary Cancer. download schema and patient eligibility summary

HEAD & NECK:

20050236 Combination Chemotherapy with or without Panitumumab as First-Line Treatment of Subjects with Metastatic or Recurrent Head & Neck Cancer, and Cross-Over Second-Line Panitumumab Monotherapy of Subjects Who Fail the Combination Only Arm. download schema and patient eligibility summary

20062088 Second-Line Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head & Neck. download schema and patient eligibility summary

RTOG-0522 Concurrent Accelerated Radiation and Cisplatin vs Concurrent Accelerated Radiation, Cisplatin, and Erbitux (Followed by Surgery for Selected Patients) for Stage III and IV Head and Neck Carcinomas. download schema and patient eligibility summary

LEUKEMIA:

    ALL:

C10403 (SWOG) Untreated Acute Lymphoblastic Leukemia. download schema and patient eligibility summary

S0530 Cytarabine and Clolar in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia. download schema and patient eligibility summary

    AML:

E1905 Vidaza with or without MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Displastic Type), and Acute Myeloid Leukemia with Multilineage Dysplasia. download schema and patient eligibility summary

S0106 Mylotarg Induction Therapy vs Standard Induction with Daunomycin and Cytarbine followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Mylotarg or No Additional Therapy for Patients Undar Age 56 with Previously Untreated DeNovo AML. download schema and patient eligibility summary

    LEUKEMIA OTHER:

CALGB-10501 (CTSU) Asymptomatic Patients with Untreated Chronic Lymphoctyic Leukemia: Early Intervention vs Observation with Later Treatment in the High Risk Genetic Subset with IgVh Unmutated Disease. download schema and patient eligibility summary

N0683 Sutent for Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). download schema and patient eligibility summary

S0535 Trisenox and Mylotarg in Patients with Previously Untreated High-Risk Acute Promyelocytic Leukemia. download schema and patient eligibility summary

    LEUKEMIA COMPANION:

S9910 Leukemia Central Ref Lab, Tissue Reposit download schema and patient eligibility summary

SWOG-9007 Cytogenetic Studies in Leukemia Patients

LUNG:

    LUNG CANCER CONTROL:

E5597 Chemoprevention Trial of Selenium Supplementation in Persons with Resected Stage I NSCLC. download schema and patient eligibility summary

S0424 Molecular Epidemiology Case-Series Study of NSCLC in Non-Smoking Women and Men. download schema and patient eligibility summary

    MESOTHELIOMA:

N0623 Pazopanib (GW786034) in Patients with Malignant Pleural Mesothelioma. download schema and patient eligibility summary

    NSCLC:

ACOSOG-Z4032 Sublobar Resection vs Sublobar Resection Plus Brachytherapy in High-Risk Patients with NSCLC, 3cm or Smaller. download schema and patient eligibility summary

E1505 Adjuvant Chemotherapy with or without Avastin for Patients with Completely Resected Stage IB(>=4 cm)-IIIA Non-Small Cell Lung Cancer. download schema and patient eligibility summary

N0626 Alimta with Nexavar vs Alimta Alone as Second-line Therapy in Patients with Advanced Non-Small Cell Lung Cancer. download schema and patient eligibility summary

S0636 Combination of Tarceva and Avastin in Never-Smokers with Stage IIIB and IV Primary NSCLC Adenocarcinomas. download schema and patient eligibility summary

    SCLC:

AVF3995g Avastin in Previously Untreated Extensive-Stage Small Cell Lung Cancer. download schema and patient eligibility summary

N0621 c-SRC Inhibitor AZD0530 After Four Cycles of Cytoreductive Chemotherapy for Patients with Extensive Stage Small Cell Lung Carcinoma. download schema and patient eligibility summary

    LUNG OTHER:

S0526 Alimta in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma. download schema and patient eligibility summary

S0635 Combination of Tarceva and Avastin in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma with BAC Features. download schema and patient eligibility summary

    LUNG COMPANION:

S9925 Lung Cancer Specimen Repository

LYMPHOMA:

    B-CELL:

S0520 PXD101 in Relapsed and Refractory Aggressive B-Cell Lymphomas. download schema and patient eligibility summary

    HODGKIN'S:

S0410 Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin's Disease. download schema and patient eligibility summary

    MANTLE CELL:

N038H Rapamycin analog in Combination with Rituxan in Patients with Relapsed or Refractory Mantle Cell Lymphoma. download schema and patient eligibility summary

    NHL:

BMTCTN-0401 Phase III Rituxan/BEAM vs Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non=Hodgkin's Lymphoma. download schema and patient eligibility summary

E4402 Two Different Rituxan Dosing Regimens for Patients with Low Tumor Burden Indolent NHL. download schema and patient eligibility summary

MC0485 Oxaliplatin, Cytarbine, Cexamethasone with Rituxan in Patients with Relapsed CD20+ B-Cell NHL. download schema and patient eligibility summary

S0016 CHOP + Rituxan vs. CHOP + Bexxar for Treatment of Newly Diagnosed Follicular NHL. download schema and patient eligibility summary

S0433 Bexxar in Combination with Cytoxan, Adriamycin, Vincristine, Prednisone and Rituxan Therapy for Patients with Advanced Stage Diffuse Large B-Cell NHL. download schema and patient eligibility summary

    LYMPHOMA COMPANION:

S8947 Central Lymphoma Serum Repository Protocol

SWOG-8819 Central Lymphoma Repository Tissue Procurement Protocol

MELANOMA:

E1697 Four Weeks of High Dose IFN-26 in Stage T3-T4 or N1 (Microscopic) Myeloma. download schema and patient eligibility summary

LX01-315-01 Treatment with 2mg Intralesional Allovectin-7 Compared to Dacarbazine or Temodar in Subjects with Recurrent Metastatic Melanoma. download schema and patient eligibility summary

N0675 Temodar and Everolimus Therapy for Metastatic Melanoma. download schema and patient eligibility summary

MYELOMA:

    MYELOMA CANCER CONTROL:

CZOL446EUS129 Bone Marker Directed Dosing of Zometa for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma. download schema and patient eligibility summary

    MYELOMA TREATMENT:

C05009 Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High Dose Chemotherapy and Autologous Stem Cell Transplantation: Velcade, Thalidomide, and Dexamethasone vs Velcade and Dexamethasone vs Velcade, Melphalan, and Prednisone. download schema and patient eligibility summary

E1A05 Consolidation Therapy with Velcade-Revlimid-Dexamethasone vs Velcade-Dexamethasone for Patients with Multiple Myeloma Who Have Completed a Dexamethasone Based Induction Regimen. download schema and patient eligibility summary

S0777 Revlimid and Low Dose Dexamethasone vs Velcade, Revlimid and Low Dose Dexamethasone for Induction, in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant. download schema and patient eligibility summary

    MYELOMA COMPANION:

S0309 Myeloma Specimen Repository Protocol, Ancillary download schema and patient eligibility summary

OTHER:

N0392 Assessment of Patient Satisfaction with Participation on Phase II/III NCCTG Clinical Trials. download schema and patient eligibility summary